-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $153

Benzinga·08/06/2026 14:48:59
Listen to the news
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $151 to $153.